Evidence map›Paper›PMID 42156955›Full record

ArticleCommunications biology2026

Tetrameric assembly disruption impairs CXCL4 chaperon ability for DNA and type I interferon immune amplification.

Giuseppe Ocone, Anna Mennella, Immacolata Pietraforte, Raffaella Palazzo, Francesca R Spinelli, Lucia Gaddini, Katia Stefanantoni, Valeria Riccieri, Ernest Y Lee, Gerard C L Wong and 2 more

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Giuseppe Ocone *Istituto Superiore di Sanità, National center for Global Health, Roma, Italy.ORCID http://orcid.org/0009-0005-4711-4122
Anna Mennella *Istituto Superiore di Sanità, National center for Global Health, Roma, Italy.
Immacolata PietraforteDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Raffaella PalazzoIstituto Superiore di Sanità, National center for Global Health, Roma, Italy.
Francesca R SpinelliDepartment of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Roma, Italy.
Lucia GaddiniIstituto Superiore di Sanità, National Center for drug research and evaluation, Roma, Italy.ORCID http://orcid.org/0000-0002-0729-8001
Katia StefanantoniDepartment of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Roma, Italy.
Valeria RiccieriDepartment of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Roma, Italy.
Ernest Y LeeDepartment of Bioengineering, Department of Chemistry & Biochemistry, and California, NanoSystems Institute, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-5144-2552
Gerard C L WongDepartment of Bioengineering, Department of Chemistry & Biochemistry, and California, NanoSystems Institute, University of California, Los Angeles, CA, USA.
Roberto LandeIstituto Superiore di Sanità, National center for Global Health, Roma, Italy.
Loredana FrascaIstituto Superiore di Sanità, National center for Global Health, Roma, Italy. loredana.frasca@iss.it.ORCID http://orcid.org/0000-0001-6924-3826

Funding

UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
UCSF Dermatology Training GrantT32AR007175 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Wilson Liao, Michael David Rosenblum · 1986 to 2026
$6.1M
Dermatology Scientist Training ProgramT32AR071307 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MODLIN, ROBERT L · 2017 to 2021
$1.1M
Ministero degli Affari Esteri e della Cooperazione Internazionale (Ministry of Foreign Affairs and International Cooperation) Italy-India cooperation project (cod.: PGR02038)NIAMS NIH HHS T32 AR007175NIAMS NIH HHS T32 AR071307NIGMS NIH HHS T32 GM008042
6 · The paper itself

Abstract

Chemokine (C-X-C motif) ligand 4 (CXCL4), an antimicrobial chemokine with multiple effector functions, is a known biomarker in systemic sclerosis (SSc), but it also plays important roles in inflammatory bowel diseases, atopic dermatitis, psoriasis, systemic lupus erythematosus and other chronic inflammatory diseases. In SSc, the presence of CXCL4 correlates with severe disease progression: CXCL4 contributes to the interferon-(IFN)-I signature by forming pro-inflammatory liquid crystalline complexes with self-DNA, which have the capacity to activate TLR9 in a multivalent manner and potently induce IFN-α in plasmacytoid dendritic cells. Here, we show that in order to chaperone DNA to amplify TLR9 responses effectively, CXCL4 needs to retain its ability to assemble into tetramers, in addition to forming the optimal liquid crystalline structure. By comparing various mutated CXCL4 derived peptides with altered cationic charge and with ablated capacity to from stable tetramers, we find the surprising result that the physiological pre-assembly of CXCL4 into tetramers, before DNA interaction, is important for strong amplified IFN-I secretion. Most importantly, small molecules that destabilize CXCL4 tetramerization block the plasmacytoid dendritic cells IFN-α response, suggesting new pharmacological interventions in SSc, and possibly in other autoimmune conditions characterized by the presence of high CXCL4 and CXCL4-DNA complexes expression.

Indexed as

DNAInterferon Type IMolecular ChaperonesPlatelet Factor 4Dendritic CellsHumansProtein MultimerizationDNAInterferon Type IMolecular ChaperonesPF4 protein, humanPlatelet Factor 4

Identifiers

PMID42156955
PMCPMC13454607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.